RxDoctor Payments Data

Hammad Hafeez, MD

Hospitalist · Fredericksburg, VANPI 1427044205

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Among hospitalist clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,236in general payments, 2019–2025

Across 61 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$216
  • Novo Nordisk$153
  • Novartis$95
  • Madrigal Pharmaceuticals$64
  • Vifor Pharma, Inc.$63
  • Stryker$61
  • plus $585 from 21 others

What the payments were for

  • Food & beverage$1,236100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,236 in reported general payments places this provider in the 95th percentile of 539 hospitalist providers in Virginia.

See all hospitalist providers in Virginia

Medicare billing

Part B allowed, 2024
$151,250
Medicare patients
709
Services billed
1,491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$40,394
Daptomycin26$6,621
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$4,228
XareltoRivaroxaban15$3,603
Pantoprazole Sodium105$3,475
Atorvastatin Calcium136$2,876
Meropenem13$2,477
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$2,172
Omeprazole77$1,976
Amlodipine Besylate131$1,708
Donepezil Hcl31$1,371
Levothyroxine Sodium92$1,367
Carvedilol79$1,346
Lubiprostone14$1,185
Metoprolol Tartrate108$1,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$40,39488 claims
Johnson & JohnsonXarelto$216$3,60315 claims
Novo NordiskNovolog$153$90411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 539 hospitalist providers in Virginia.

Other hospitalist in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →